Periasamy Selvaraj, PhD

Research Program

Cancer Immunology
Phone Number

404-727-5929
Email Address

pselvar(at)emory.edu

Biography

Periasamy Selvaraj, PhD, is a professor in the Department of Pathology and Laboratory Medicine at Emory University School of Medicine. Dr. Selvaraj is also a co-founder of Metaclipse Therapeutics Corporation, a biotech company focusing on developing personalized immunotherapy for metastatic cancer. He is a member of the Cancer Immunology Research Program at Winship Cancer Institute of Emory University in Atlanta, Georgia.

Education

Dr. Selvaraj earned his PhD in Biochemistry from Christian Medical College, Vellore, and his MSc in Biochemistry from the University of Madras, Chennai, India. After obtaining his PhD, Dr. Selvaraj completed a postdoctoral fellowship at Dana-Farber Cancer Institute and Harvard Medical School, where he also served as an Instructor in the Department of Pathology. His postdoctoral work under the supervision of Dr. Timothy A. Springer focused on cell adhesion receptors of the immune system.

Titles & Roles

Professor, Department of Pathology and Laboratory Medicine

Emory University School of Medicine

Research

Dr. Selvaraj's laboratory focuses on developing personalized cancer vaccine-based immunotherapy approaches using a novel protein transfer technology and patients tumor tissue and studying the role and regulation of Fc receptors in antibody-mediated immunity and inflammation.

Publications

Dr. Selvaraj has published more than 90 research papers in national and international journals.

Title/Journal	Authors	Publication Date
Hemagglutinin virus-like particles incorporated with membrane-bound cytokine adjuvants provide protection against homologous and heterologous influenza virus challenge in aged mice. Immunity & ageing : I & A	BR Park, R Bommireddy, DH Chung, KH Kim, J Subbiah, YJ Jung, N Bhatnagar, CD Pack, S Ramachandiran, SJC Reddy, P Selvaraj, SM Kang	11/05/2023
The magic of small-molecule drugs during ex vivo expansion in adoptive cell therapy. Frontiers in immunology	H Zhang, T Passang, S Ravindranathan, R Bommireddy, MR Jajja, L Yang, P Selvaraj, CM Paulos, EK Waller	01/01/2023
Influenza Virus-like Particle-Based Hybrid Vaccine Containing RBD Induces Immunity against Influenza and SARS-CoV-2 Viruses. Vaccines	R Bommireddy, S Stone, N Bhatnagar, P Kumari, LE Munoz, J Oh, KH Kim, JTL Berry, KM Jacobsen, L Jaafar, SH Naing, AN Blackerby, TV Gaag, CN Wright, L Lai, CD Pack, S Ramachandiran, MS Suthar, SM Kang, M Kumar, SJC Reddy, P Selvaraj	14/06/2022
Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapy. Journal for immunotherapy of cancer	LE Munoz, L Huang, R Bommireddy, R Sharma, L Monterroza, RN Guin, SG Samaranayake, CD Pack, S Ramachandiran, SJC Reddy, M Shanmugam, P Selvaraj	01/11/2021
Dendritic Cells Pulsed with Cytokine-Adjuvanted Tumor Membrane Vesicles Inhibit Tumor Growth in HER2-Positive and Triple Negative Breast Cancer Models. International journal of molecular sciences	LE Munoz, L Monterroza, R Bommireddy, Y Shafizadeh, CD Pack, S Ramachandiran, SJC Reddy, P Selvaraj	04/08/2021
Expression of tdTomato and luciferase in a murine lung cancer alters the growth and immune microenvironment of the tumor. PloS one	L Huang, R Bommireddy, LE Munoz, RN Guin, C Wei, A Ruggieri, AP Menon, X Li, M Shanmugam, TK Owonikoko, SS Ramalingam, P Selvaraj	01/01/2021
Tumor membrane-based vaccine immunotherapy in combination with anti-CTLA-4 antibody confers protection against immune checkpoint resistant murine triple-negative breast cancer. Human vaccines & immunotherapeutics	CD Pack, R Bommireddy, LE Munoz, JM Patel, EN Bozeman, P Dey, V Radhakrishnan, VF Vartabedian, K Venkat, S Ramachandiran, SJC Reddy, P Selvaraj	01/12/2020
Doxorubicin Conjugation to Reovirus Improves Oncolytic Efficacy in Triple-Negative Breast Cancer. Molecular therapy oncolytics	JTL Berry, LE Muñoz, RM Rodríguez Stewart, P Selvaraj, BA Mainou	25/09/2020
Tumor Membrane Vesicle Vaccine Augments the Efficacy of Anti-PD1 Antibody in Immune Checkpoint Inhibitor-Resistant Squamous Cell Carcinoma Models of Head and Neck Cancer. Vaccines	R Bommireddy, LE Munoz, A Kumari, L Huang, Y Fan, L Monterroza, CD Pack, S Ramachandiran, SJC Reddy, J Kim, ZG Chen, NF Saba, DM Shin, P Selvaraj	14/04/2020
Effects of anchor structure and glycosylation of Fcγ receptor III on ligand binding affinity. Molecular biology of the cell	N Jiang, W Chen, P Jothikumar, JM Patel, R Shashidharamurthy, P Selvaraj, C Zhu	07/11/2016
Plasma membrane vesicles decorated with glycolipid-anchored antigens and adjuvants via protein transfer as an antigen delivery platform for inhibition of tumor growth. Biomaterials	JM Patel, VF Vartabedian, EN Bozeman, BE Caoyonan, S Srivatsan, CD Pack, P Dey, MJ D'Souza, L Yang, P Selvaraj	01/01/2016
Therapeutic efficacy of PD-L1 blockade in a breast cancer model is enhanced by cellular vaccines expressing B7-1 and glycolipid-anchored IL-12. Human vaccines & immunotherapeutics	EN Bozeman, S He, Y Shafizadeh, P Selvaraj	01/01/2016
Immune Complex-Induced, Nitric Oxide-Mediated Vascular Endothelial Cell Death by Phagocytes Is Prevented with Decoy FcγReceptors. PloS one	RV Mula, D Machiah, L Holland, X Wang, H Parihar, AC Sharma, P Selvaraj, R Shashidharamurthy	01/01/2016
Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responses. Nanomedicine : nanotechnology, biology, and medicine	JM Patel, MC Kim, VF Vartabedian, YN Lee, S He, JM Song, HJ Choi, S Yamanaka, N Amaram, A Lukacher, CD Montemagno, RW Compans, SM Kang, P Selvaraj	01/07/2015
Influenza virus-like particles engineered by protein transfer with tumor-associated antigens induces protective antitumor immunity. Biotechnology and bioengineering	JM Patel, VF Vartabedian, MC Kim, S He, SM Kang, P Selvaraj	01/06/2015
Antibody effector functions mediated by Fcγ-receptors are compromised during persistent viral infection. Immunity	A Wieland, R Shashidharamurthy, AO Kamphorst, JH Han, RD Aubert, BP Choudhury, SR Stowell, J Lee, GA Punkosdy, MJ Shlomchik, P Selvaraj, R Ahmed	17/02/2015
Theranostic nanoparticles carrying doxorubicin attenuate targeting ligand specific antibody responses following systemic delivery. Theranostics	E Yang, W Qian, Z Cao, L Wang, EN Bozeman, C Ward, B Yang, P Selvaraj, M Lipowska, YA Wang, H Mao, L Yang	01/01/2015
Allogeneic tumor cell vaccines: the promise and limitations in clinical trials. Human vaccines & immunotherapeutics	S Srivatsan, JM Patel, EN Bozeman, IE Imasuen, S He, D Daniels, P Selvaraj	01/01/2014
Cancer CARtography: charting out a new approach to cancer immunotherapy. Immunotherapy	JM Patel, GA Dale, VF Vartabedian, P Dey, P Selvaraj	01/01/2014
Expression of membrane anchored cytokines and B7-1 alters tumor microenvironment and induces protective antitumor immunity in a murine breast cancer model. Vaccine	EN Bozeman, A Cimino-Mathews, DK Machiah, JM Patel, A Krishnamoorthy, L Tien, R Shashidharamurthy, P Selvaraj	07/05/2013
Differential role of lipocalin 2 during immune complex-mediated acute and chronic inflammation in mice. Arthritis and rheumatism	R Shashidharamurthy, D Machiah, JD Aitken, K Putty, G Srinivasan, B Chassaing, CA Parkos, P Selvaraj, M Vijay-Kumar	01/04/2013
Ukrain, a plant derived semi-synthetic compound, exerts antitumor effects against murine and human breast cancer and induce protective antitumor immunity in mice. Experimental oncology	EN Bozeman, S Srivatsan, H Mohammadi, D Daniels, R Shashidharamurthy, P Selvaraj	01/12/2012
Taming dendritic cells with TIM-3: another immunosuppressive strategy used by tumors. Immunotherapy	J Patel, EN Bozeman, P Selvaraj	01/12/2012
Formulation and evaluation of a particulate oral breast cancer vaccine. Journal of pharmaceutical sciences	L Chablani, SA Tawde, A Akalkotkar, C D'Souza, P Selvaraj, MJ D'Souza	01/10/2012
Hydrodynamic delivery of plasmid DNA encoding human FcγR-Ig dimers blocks immune-complex mediated inflammation in mice. Gene therapy	R Shashidharamurthy, D Machiah, EN Bozeman, S Srivatsan, J Patel, A Cho, J Jacob, P Selvaraj	01/09/2012
Formulation and evaluation of oral microparticulate ovarian cancer vaccines. Vaccine	SA Tawde, L Chablani, A Akalkotkar, C D'Souza, M Chiriva-Internati, P Selvaraj, MJ D'Souza	17/08/2012
Oral microparticulate vaccine for melanoma using M-cell targeting. Journal of drug targeting	B D'Souza, T Bhowmik, R Shashidharamurthy, C Oettinger, P Selvaraj, M D'Souza	01/02/2012
A novel microparticulate vaccine for melanoma cancer using transdermal delivery. Journal of microencapsulation	T Bhowmik, B D'Souza, R Shashidharamurthy, C Oettinger, P Selvaraj, MJ D'Souza	01/01/2011
Immune complex-mediated enhancement of secondary antibody responses. Journal of immunology (Baltimore, Md. : 1950)	CL Goins, CP Chappell, R Shashidharamurthy, P Selvaraj, J Jacob	01/06/2010
Cancer vaccine development: designing tumor cells for greater immunogenicity. Frontiers in bioscience (Landmark edition)	EN Bozeman, R Shashidharamurthy, SA Paulos, R Palaniappan, M D'Souza, P Selvaraj	01/01/2010
Dynamics of the interaction of human IgG subtype immune complexes with cells expressing R and H allelic forms of a low-affinity Fc gamma receptor CD32A. Journal of immunology (Baltimore, Md. : 1950)	R Shashidharamurthy, F Zhang, A Amano, A Kamat, R Panchanathan, D Ezekwudo, C Zhu, P Selvaraj	15/12/2009
'Exhaustive' look at PD-1/PDL-1 blockade in vivo. Immunotherapy	EN Bozeman, JD Hood, R Shashidharamurthy, P Selvaraj	01/07/2009
Inhibition of expression of anti-apoptotic protein Bcl-2 and induction of cell death in radioresistant human prostate adenocarcinoma cell line (PC-3) by methyl jasmonate. Cancer letters	D Ezekwudo, R Shashidharamurthy, D Devineni, E Bozeman, R Palaniappan, P Selvaraj	08/11/2008
Extravasations and emigration of neutrophils to the inflammatory site depend on the interaction of immune-complex with Fcgamma receptors and can be effectively blocked by decoy Fcgamma receptors. Blood	R Shashidharamurthy, RA Hennigar, S Fuchs, P Palaniswami, M Sherman, P Selvaraj	15/01/2008
Custom designing therapeutic cancer vaccines: delivery of immunostimulatory molecule adjuvants by protein transfer. Human vaccines	P Selvaraj, A Yerra, L Tien, R Shashidharamurthy	01/01/2008

Awards

In 2016, Dr. Selvaraj received the Emory 1% Award which recognizes Emory faculty whose National Institutes of Health (NIH) proposals have been ranked in the top 1% by NIH reviewers.